Save up -80% on Alirocumab
Note: this is a drug discount program, not an insurance plan.
2018 Price of Alirocumab
* price without discount in nearest pharmacy. Price may vary.
We offer free Alirocumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Alirocumab every time. What are you waiting for? Claim your prescription drug card now!
Alirocumab volume of distribution
Alirocumab is mainly distributed through the circulatory system, with minimal extravascular distribution.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Alirocumab
Alirocumab is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Alirocumab mechanism of action
Alirocumab is a fully human IgG1 monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme found to have “gain of function” mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and typically binds to the LDL receptors in serum and marks them for lysosomal degradation. In result, the LDL receptors are not able to recycle to the plasma membrane, reducing their binding to LDL-C and therefore reducing the clearance of LDL-C from plasma. Therefore by inhibiting PCSK9’s actions, alirocumab allows for more LDL-C reuptake by the liver and facilitates a higher rate of clearance. Lower LDL cholesterol concentrations are associated with a reduced risk of coronary heart disease.
Dosage forms of Alirocumab
|Injection, solution||subcutaneous||150 mg/mL|
|Injection, solution||subcutaneous||75 mg/mL|
Sanofi Aventis Canada Inc
Indication of Alirocumab
Alirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
Toxicity of Alirocumab
RX24 Drugs Disclaimer: before buying a Alirocumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.